5
5 Diagnosis of chronic heart failure
Pages 21–31 · open in PDF
Recommendations in this section
- Class ILevel CIn patients with suspected HF, the following laboratory tests are recommended when screening for comorbidities: full blood count, kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin).
- Class ILevel CNatriuretic peptide measurement is recommended in patients with suspected HF (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic peptide level).
- Class ILevel CA 12-lead ECG is recommended in patients with suspected HF.
- Class ILevel CChest radiography (X-ray) is recommended in patients with suspected HF.
- Class ILevel CTransthoracic echocardiogram is recommended in patients with suspected HF to confirm the diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of HF.
- Class ILevel CContrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.
- Class ILevel BInitial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.
- Class ILevel CGenetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.
- Class ILevel CInvasive coronary angiography is recommended in patients with HF, angina, and high probability of obstructive CAD who are potential candidates for revascularization.
- Class IIaLevel C18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.
- Class IIaLevel CEndomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.
- Class IIaLevel CRight heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease.
- Class IIbLevel CRight heart catheterization may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state.
- Class IIaLevel CInvasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihood of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.
- Class IIaLevel CCTCA should be considered in patients with HFrEF and low-moderate pre-test likelihood of obstructive CAD.
- Class IIaLevel CReview of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.
- Class IIbLevel CElectrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 21 · PDF
4.2.1. Asymptomatic left ventricular dysfunction Based on normal reference values of LVEF in adult populationbased samples, LV systolic dysfunction should be considered present if patients are asymptomatic and have an LVEF <50% in the absence of alternative explanations (e.g. athlete’s heart) for both men and women and regardless of age. Treatment with an ACE-I (or ARB if intolerant) if LVEF ≤40% and a beta-blocker if LVEF <50% are recommended to reduce the risk of HF and mortality. The evidence behind these recommendations are derived from the SOLVD-Prevention trial,135,136 which randomized patients with asymptomatic LV systolic dysfunction (LVEF ≤35%) to enalapril or placebo, and the TRACE137 and SAVE138 trials, which randomized patients post-MI with LVEF ≤35%–40% to trandolapril or placebo (TRACE) and captopril vs placebo (SAVE). These studies were conducted in the 1990s and contemporary management of multiple comorbidities (MI, diabetes, CKD) has since changed. One RCT, CAPRICORN, published in 2001, investigated beta-blockers post-MI in patients with LV systolic dysfunction, where patients were randomized to carvedilol or placebo.139 It should be noted that this trial allowed patients to receive intravenous (i.v.) diuretics for acute HF, but excluded those with continuous need for i.v. diuretics, meaning not all had truly asymptomatic LV systolic dysfunction. The hazard ratio (HR) for all-cause mortality was 0.77 [95% confidence interval (CI) 0.60–0.98] in the group receiving carvedilol vs placebo. Additional observational data from SOLVD and SAVE suggested similar improved outcomes with a beta-blocker.140–142 Further, the REVERT trial, which randomized asymptomatic patients with LVEF <40% to metoprolol extended release or placebo, showed that metoprolol reversed LV remodelling.142 The role of these drugs for asymptomatic individuals with mildly reduced LVEF (41%–49%) is not well studied, but their use is reasonable also in this range of LVEF given the shared pathophysiology with more depressed LV systolic function. A meta-analysis of BETAMI–DANBLOCK and REBOOT-CNIC showed a significant reduction in the combined endpoint of mortality, MI and HF with beta-blockers vs placebo in post-MI patients with stage B HF and mildly reduced LVEF.121 Careful follow-up to assess for progressive decline in LVEF is otherwise warranted for patients without treatment. Based on the results of the EPHESUS trial, eplerenone is recommended in patients after MI with LVEF ≤40% and diabetes to reduce the risk of HFH or death.143
4.2.2. Valvular heart disease Prevention of HF in patients with valvular disease should follow the recommendations outlined in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9
Recommendations An ACE-I or ARB (if intolerant to ACE-I) is recommended in patients with stage B HF and LVEF ≤40% to reduce the risk of HFH and
death.135–138,144 A beta-blocker is recommended in patients with stage B HF and LVEF <50% to reduce the risk of HFH or death.35,139,140 Eplerenone is recommended in patients with LVEF ≤40% after myocardial infarction with signs of HF or diabetes to reduce the risk of HFH and death.143
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction. a Class of recommendation. b Level of evidence.
4.3. Risk prediction in patients with established heart failure Several risk scores have been developed to predict HFH and mortality among ambulatory patients with established HF, including e.g. the MAGGIC risk score,77 the Seattle Heart Failure Model,78 and the more recent ESC initiated LIFE-HF79 (HFrEF) and LIFE-Preserved (HFpEF).80 It should be noted that LIFE-HF included patients with LVEF ≤40% and LIFE-Preserved patients with LVEF ≥50%. The ESC scores therefore need to be validated for HFrEF patients in the upper range of LVEF (>40%–49%) and, ideally, in external samples across the entire LVEF spectrum before widespread implementation (see Supplementary data online, Section S1 and Figure S1). Although pharmacological treatments are indicated in patients with established HF regardless of estimated risks (as outlined in Section 6), these risk scores may be helpful in identifying high-risk patients that may benefit from closer follow-up and to facilitate discussions around patient goals of care.
5. Diagnosis of chronic heart failure 5.1. Key steps in the diagnosis of chronic heart failure The failing heart causes a clinical syndrome with a wide array of signs and symptoms, which vary in sensitivity and specificity (Table 7), and none of which are entirely characteristic. The severity of HF symptoms can be classified according to the New York Heart Association (NYHA) functional class (Table 8). Specialist assessment relies on clinical evaluation, the examination of individual risk factors, and previous medical history as well as 12-lead ECG and chest X-ray evaluation. Clinical suspicion should be followed by testing of natriuretic peptides and echocardiography (Figure 4). In the very elderly patients, suspicion should be raised even with an atypical presentation. A recent HFA consensus paper provides a diagnostic framework for general practice and non–cardiology-based physicians.145
4.2. Patients with stage B heart failure
Recommendation Table 2 — Recommendations for stage B heart failure and left ventricular dysfunction (see Evidence Table 16)
(e.g. tetralogy of Fallot, transposition of the great arteries, truncus arteriosus, double-outlet right or left ventricle, with up to 42-fold risk), and severe non-conotruncal defects (e.g. atrioventricular septal defects, single ventricle and hypoplastic left heart syndrome, with up to 21-fold increased risk).131 Conventional HF risk factors (e.g. CAD, hypertension, diabetes, and obesity) are common in patients with congenital heart disease and contribute significantly to HF risk.132–134 Careful attention to riskfactor modification is warranted as they are likely to contribute to the risk of developing HF.
Page 22 · PDF
22 Symptoms and signs of heart failure
Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity
Elevated jugular venous pressure
Paroxysmal nocturnal dyspnoea
Third heart sound (gallop rhythm)
Reduced exercise tolerance
Laterally displaced apical impulse
Severity of symptoms and physical activity
No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Fatigue, tiredness, increased
time to recover after exercise
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue, or palpitations.
Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any
Weight loss (in advanced HF)
physical activity is undertaken, discomfort is
Confusion (especially in the
Peripheral oedema (ankle, sacral,
NYHA, New York Heart Association.
Tachypnoea Cheyne–Stokes respiration Hepatomegaly Cold extremities Oliguria Narrow pulse pressure
HF, heart failure. a Elderly patients may present with more atypical symptoms of HF. b Breathlessness on bending forward/flexing the body.
5.1.1. Natriuretic peptides Adverse clinical events often occur soon after a new presentation of HF in the community; therefore, timely diagnosis and initiation of treatment are essential. Natriuretic peptide testing is recommended to support the diagnosis of HF and improves efficiency by avoiding unnecessary echocardiography and/or specialist assessment.146–150 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most widely used natriuretic peptide in the management of HF in Europe and has two key advantages: better stability at room temperature, enabling reliable testing in both hospital and community settings; and unaltered results despite treatment with ARNIs, which affect B-type natriuretic peptide (BNP) degradation.149,150 However, testing for NT-proBNP is not universally available, and some regions employ BNP or mid-regional pro-atrial natriuretic peptide (MR-proANP) testing. The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommended a single natriuretic
peptide threshold to ‘rule out’ HF (<125 pg/mL for NT-proBNP, <35 pg/mL; for BNP, <40 pg/mL; for MR-proANP). Single natriuretic peptide rule-out thresholds have the advantage of simplicity; however, natriuretic peptide levels are strongly related to age and lack specificity in older people.151 More than 75% of a healthy population >80 years were found to exceed the 125 pg/mL NT-proBNP threshold.152–156 The HFA-ESC consensus statement on NT-proBNP testing recommends introducing age-related thresholds determined from the 95th percentile of the Generation Scotland cohort to improve specificity and reduce unnecessary demand on echocardiography and HF services.157 The suggested age-adjusted NT-proBNP levels, above which HF is ‘likely’ in the outpatient setting, were ≥125 pg/mL for those aged <50 years, ≥250 pg/mL between 50 and 75 years, and ≥500 pg/mL over 75 years.151,157 Currently there are insufficient data for determining age-specific BNP cut-offs. For the diagnosis of HFpEF, natriuretic peptide interpretation may be challenging as a variety of conditions associated with HFpEF affect natriuretic peptide levels (Table 9).158 Especially obesity is associated with lower cut-off values for natriuretic peptides, and caution is advised when interpreting natriuretic peptide levels in obese patients.158–160 Reduced kidney function has been shown to be associated with higher NT-proBNP levels, although NT-proBNP measurements should not be disregarded in the setting of kidney dysfunction.161,162 Furthermore, many other factors can elevate natriuretic peptide levels (Table 9). Clinicians must consider these factors in conjunction with clinical assessment and investigation findings when interpreting natriuretic peptide measurements; however, the higher the natriuretic peptide level the greater the likelihood of HF as the diagnosis. Natriuretic peptides also provide important prognostic information, enabling rapid triage of high-risk patients. Primary care data from England demonstrate that patients with HF and NT-proBNP levels exceeding 2000 pg/mL exhibit a two-fold increased risk of early HFH. Accordingly, expedited specialist assessment of this high-risk cohort is warranted.163
Page 23 · PDF
Figure 4 Diagnostic algorithm for chronic heart failure presenting in the outpatient or community setting. BNP, B-type natriuretic peptide; CXR, chest X-ray; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; POCUS, point-of-care ultrasound; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Full blood count, kidney function, electrolytes, UACR, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin). b Examination by POCUS may aid in diagnosis although echocardiography is recommended. cNatriuretic peptides may be false low in certain settings (Table 9). dPreferable performed within 2 weeks if NT-proBNP >2000 pg/mL.
Page 24 · PDF
required in the assessment of kidney function.164 UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥90 mL/min/ 1.73 m2. UACR has strong independent prognostic value for patients with HF.165,166 Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.167
Table 9 Causes for increase or decrease in natriuretic peptide levels Causes for increased natriuretic peptide levels Acute coronary syndrome Advanced agea Atrial fibrillation Cardiac contusion Critical illness Female sex Kidney dysfunction
LV hypertrophy Myocarditis
In patients with suspected HF, the following laboratory tests are recommended when
screening for comorbidities: full blood count,
kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids,
Pulmonary embolism Pulmonary hypertension
and iron status (TSAT and ferritin).168
Natriuretic peptide measurement is (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic
Severe endocrine dysfunction Severe infections (including pneumonia and sepsis)
A 12-lead ECG is recommended in patients with
Severe metabolic acidosis and diabetic ketoacidosis
Chest radiography (X-ray) is recommended in
patients with suspected HF.
in patients with suspected HF to confirm the
African ancestry ARNI /ACE-I/ARB
diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a See Figure 4. b ARNI may raise BNP levels.
5.1.2. Other laboratory tests Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy. Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Class of recommendation. b Level of evidence. c See Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.
5.2. Heart failure phenotypes based on left ventricular ejection fraction Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.
5.2.1. Heart failure with reduced ejection fraction The diagnosis of HFrEF requires the following criteria: (i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF <50%. Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the
Transthoracic echocardiogram is recommended
Causes for decreased natriuretic peptide levels
peptide levelc).146–148,151–153,169
recommended in patients with suspected HF
Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)
Page 25 · PDF
Table 10 Simplified echocardiographic criteria for supporting objective evidence of heart failure with preserved ejection fraction Criteria
≥115 g/m2 (male) OR Relative wall thickness >0.42 LA dilatation (volume indexed by BSA)
>34 mL/m2 (sinus rhythm) >40 mL/m2 (AF)
Increased likelihood of elevated LV filling pressure
Raised estimated systolic PA pressure
>35 mmHg OR TR velocity at rest >2.8 m/s
The probability for an HFpEF diagnosis increases with the number of parameters in the pathological range. AF, atrial fibrillation; BSA, body surface area; HFpEF, heart failure with preserved ejection fraction; LA, left atrial; LV, left ventricular; PA, pulmonary artery; TR, tricuspid regurgitation. a E/e′ ≥15 is more specific, but less sensitive, for the diagnosis of HFpEF.
only a minority of patients where the diagnosis is uncertain and where establishing the diagnosis or an alternative cause of signs or symptoms is likely to affect patient management. Therefore, current guidelines do not mandate invasive haemodynamic testing in every patient with suspected HFpEF to make the diagnosis.
5.3. Aetiology and subtypes of heart failure Assessment of aetiology is fundamental for the management of HF, as treatment should, if possible, address the underlying cause. Some treatments may be aetiology dependent, and some causes of HF are potentially reversible. Disease-modifying therapies are increasingly available, and early identification and treatment can improve survival. Targeted therapies for specific cardiomyopathies are under investigation, and precise aetiological assessment will become increasingly important in the future. Aetiology assessment also determines prognosis,177 is relevant to the patient, and imperative for care planning. Common causes of HF include ischaemic heart disease, hypertension, and valvular heart disease, although a multitude of other causes and contributing factors exist (Figures 5 and 6) and often more than one possible cause may be present. Determining the aetiology often involves a multiparametric evaluation beginning with obtaining a medical history from the patient, continuing through patient examination and clinical tests (Figure 7). Often non-invasive testing accompanied by medical history will be sufficient to determine aetiology. Characteristic findings indicating the underlying
(i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF ≥50% (requires that LVEF has not previously been <50%) (iii) Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures (Table 10), supported by raised natriuretic peptides (Figure 4). Testing for elevated levels of natriuretic peptides may in most patients support the diagnosis of HFpEF. However, diagnostic thresholds for HFpEF should be critically evaluated based on patient characteristics, especially in the presence of obesity and other factors that may cause reduced natriuretic peptide levels (Table 9).158 A pragmatic approach to the diagnosis of HFpEF is advised to facilitate access to diagnosis for the large population of elderly patients potentially affected. More complicated scoring systems171,172 have shown conflicting results in the community setting, but a meta-analysis indicates acceptable specificity and sensitivity for detection of HFpEF.173–175 If employed, diagnostic scoring systems should be interpreted with caution and used primarily to raise clinical suspicion of HFpEF rather than to establish a definitive diagnosis. In cases of diagnostic uncertainty, further investigations—such as cardiopulmonary exercise testing (CPET) [including measurement of peak oxygen consumption (VO2) to confirm reduced exercise capacity and elucidate the underlying cause of dyspnoea], exercise stress echocardiography, or invasive haemodynamic assessment— may be considered.176 The gold standard, confirmatory test for the diagnosis of HFpEF is invasive haemodynamic exercise testing. An invasively measured pulmonary capillary wedge pressure of ≥15 mmHg (at rest), or ≥25 mmHg (with exercise), or an LV end-diastolic pressure ≥16 mmHg (at rest) is generally considered diagnostic. In recognition that invasive haemodynamic exercise testing is expensive and is not available in many centres worldwide, its main use should be limited to research settings or to patients with diagnostic uncertainty despite non-invasive testing. In most patients, the diagnosis of HFpEF can be made based on clinical history and echocardiographic signs (Table 10). Thus, invasive testing is indicated in
LV mass index ≥95 g/m2 (female)
5.2.2. Heart failure with preserved ejection fraction The diagnosis of HFpEF is more challenging and should start with the assessment of pre-test probability.170 Several clinical factors may contribute to or be associated with HFpEF, as illustrated in Figure 6. The more factors present the higher the likelihood of HFpEF. The following criteria must all be present for the diagnosis of HFpEF:
diagnostic pathway, especially if echocardiography is not readily available. However, many factors may cause false positive or false negative results, which should be considered when evaluating natriuretic peptide (Table 9). LVEF is a continuous measure and may differ between methods used as well as sex. For this reason, a precise value is only given as guidance. Aetiology assessment is important, as it may result in finding potential treatable and/or reversible causes. The major aetiologies of HFrEF are illustrated in Figure 5.
Page 26 · PDF
Figure 5 Major contributing causes of heart failure with reduced ejection fraction. HFrEF, heart failure with reduced ejection fraction. a
Toxic may include both drug-related and chemotherapy-related causes.
aetiology are noted in many patients at the time of echocardiography. Patients with ischaemic aetiology may have regions of akinesis/dyskinesis and thinning/aneurysm formation in the myocardial areas affected by coronary disease. Valvular disease is detected, often also with characteristic valvular findings dependent on cause (e.g. rheumatic or ischaemic), and the long-term sequelae of untreated hypertension may be observed (LV hypertrophy, aortic dilatation
with or without central aortic regurgitation). Findings consistent with other cardiomyopathies, cardiac amyloidosis (CA), or ventricular dyssynchrony in left bundle branch block (LBBB) may also be noted. When considering further investigation for CAD, noninvasive assessment is often sufficient, and before proceeding to invasive assessment the risks and benefits should be considered.178–180
Page 27 · PDF
Figure 6 Major risk factors of heart failure with preserved ejection fraction. CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction.
If an underlying cardiomyopathy is suspected or the aetiology is unclear, further imaging with cardiac magnetic resonance (CMR) imaging is recommended. We refer to the 2023 ESC Guidelines for the management of cardiomyopathies regarding specific recommendations and approaches for investigations into specific cardiomyopathies.124 An approach with laboratory and imaging tests chosen according to the five subtypes [hypertrophic cardiomyopathy (HCM), DCM, restrictive
cardiomyopathy, ARVC, and non-dilated LV cardiomyopathy] has been recommended.124 In patients with unexplained dyspnoea, CPET may be used to identify the cause of unexplained dyspnoea and/or exercise intolerance. When a specific aetiology is suspected, further investigations may be required, such as 18F-fluorodeoxyglucosepositron emission tomography (18F-FDG-PET) for suspected
Page 28 · PDF
cardiac sarcoidosis (see Supplementary data online, Table S2).181,182 Genetic testing may be appropriate when a genetic cause is suspected and the results may provide management and prognostic guidance, result in cascade family screening or reproductive management. For more specific guidance on genetic testing in specific cardiomyopathies, we refer to the 2023 ESC Guidelines for the management of cardiomyopathies.48,124
Multimodal cardiac imaging plays a pivotal role in the diagnosis, management, and prognostic assessment of HF, enabling precise subtyping to aid in disease-specific therapy selection and is supported by a growing body of evidence (Figure 7).
Figure 7 Multiparametric approach to aetiology assessment in heart failure. 18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono1,2-propanodicarboxylic acid; ECG, electrocardiogram; EMB, endomyocardial biopsy; HMPD, hydroxymethylene diphosphonate; ICA, invasive coronary angiography; PYP, pyrophosphate; RHC, right heart catheterization.
5.3.1. Cardiac imaging in heart failure: a multimodality approach
Echocardiography is considered the first-line imaging modality in HF and remains the cornerstone of assessment. Echocardiography has widespread availability, is noninvasive, and provides the ability for real-time dynamic evaluation of cardiac structures, dimensions, volumes, filling patterns, haemodynamics, and function. Tissue Doppler imaging and speckle-tracking echocardiography have allowed clinicians to quantify myocardial global longitudinal strain, offering more sensitive measures of early systolic dysfunction even before LVEF declines, which is of particular value in patients undergoing chemotherapy, or specific strain patterns that may be suggestive of amyloidosis or HCM.183–185 In patients with HFpEF, diastolic stress testing is emerging as an important tool to unmask diastolic dysfunction that may not be apparent at rest. Depending on echocardiography findings, additional imaging modalities or
Page 29 · PDF
(Figure 8). For frail patients, a typical medical history of angina accompanied by echocardiography showing coronary territory scarring or regional wall motion abnormalities may suffice. In patients with potential for revascularization, further examinations may be needed, considering individual risks and benefits. Computed tomography coronary angiography (CTCA) has a high negative predictive value and should be considered in patients with HF when the likelihood of CAD is low to moderate.196 If patients are possible candidates for revascularization, invasive coronary angiography (ICA) is indicated in patients with HFrEF with a high likelihood of CAD and in patients with angina, regardless of LVEF. Computed tomography coronary angiography and ICA should be used with caution in patients with eGFR <30 mL/ min/1.73 m2 and/or contraindication for contrast medium administration. Evidence supporting the efficacy of viability testing to identify suitable patients for revascularization is lacking.178,179
5.3.2. Investigations for coronary artery disease
5.3.3. Heart failure caused by arrhythmia or conduction disease
Coronary artery disease is highly prevalent in HF and the most common cause of HFrEF.13,33,195 Even though assessment of aetiology is essential in HF, investigations for CAD should be tailored to the individual patient’s risks and benefits
Arrhythmia-associated HF is a broad term that encompasses HF caused by tachyarrhythmias, including AF, atrial flutter, other supraventricular tachycardias, ventricular tachycardia, and premature ventricular contraction (PVC).197,198 The identification
Figure 8 Diagnosis of heart failure due to ischaemic aetiology. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CTCA,
computed tomography coronary angiography; CV, cardiovascular; HF, heart failure; LV, left ventricular. aStress tests include stress echocardiography, stress CMR, or nuclear imaging. Electrocardiographic exercise test has not been shown to properly assess coronary stress.
testing may be needed (see Supplementary data online, Table S2). Advances in multimodal imaging, including CMR, stress testing, and computed tomography (CT), have significantly enhanced our capacity to comprehensively assess HF, offering complementary information that is crucial in complex cases.183–185 CMR is considered the gold standard for assessing LV volumes and mass, owing to its high spatial resolution and reproducibility. Late gadolinium enhancement (LGE) provides detailed insights into fibrosis and scarring and is useful in distinguishing ischaemic from non-ischaemic aetiology as well as certain cardiomyopathies.124 CMR myocardial tissue characterization with parametric mapping [T1, T2, T2* (longitudinal, transverse, and observed transverse relaxation times), LGE and extracellular volume (ECV) expansion] enables classification of cardiomyopathies124,186–193 and of cardiac amyloid.194 An overview of typical CMR findings in cardiomyopathies can be found in the 2023 ESC Guidelines for the management of cardiomyopathies.124 Description of other specific imaging modalities is provided in the Sections on specific comorbidities.
Page 30 · PDF
The diagnosis is a diagnosis of elimination, and it may only be reached retrospectively, if LV function improves following cardiac resynchronization therapy (CRT) implantation.204 In terms of likelihood of response, there is a spectrum. At one end, abnormal cardiac conduction may be the sole culprit, whereas at the other, it may be a bystander in the context of HF due to other causes (Figure 9). CMR may be useful in identifying myocardial scar and morphological abnormalities pointing to other aetiologies of HF. Abnormal cardiac conduction, as the sole cause of HFrEF, is most likely in patients with HFrEF, LBBB, wide QRS duration, with no myocardial scarring on CMR and in patients with RV pacing-induced HF.199
Recommendation Table 4 — Recommendations for specialized diagnostic investigations in patients with established heart failure to detect reversible/treatable causes of heart failure (see Evidence Tables 20–28) Classa
Invasive coronary angiography is recommended in patients with HF, angina, and high probabilityc of obstructive CAD who are potential candidates for revascularizationd.
18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.181,182
Recommendations Investigations for underlying aetiology in patients with HFpEF or HFrEF Contrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.205–215 Initial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.216–222 Genetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.223–227
Endomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.228 Right heart catheterizatione should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease.229 Right heart catheterizationf may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state.230,231 Invasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihoodc of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.178–180 CTCA should be considered in patients with HFrEF and low-moderate pre-test likelihoodc of obstructive CAD.196,232–234 Review of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.202,235–239 Electrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.240
18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; AF, atrial fibrillation; CAD, coronary artery disease; CIED, cardiac implantable electronic device; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HMDP, hydroxymethylene diphosphonate; PYP, pyrophosphate; RV, right ventricular. a Class of recommendation. b Level of evidence. c Based on cardiovascular risk factors and clinical history. d Exclude frailty, multiple severe comorbidities, limited life expectancy. e Right and left heart catheterization needed for the differential diagnosis of constrictive pericarditis and restrictive cardiomyopathy. f Potentially including exercise right heart catheterization.
Investigations for patients with HFrEF
of arrhythmia-associated HF is important in patients with HFrEF, in whom a rhythm strategy for AF may potentially be beneficial. The diagnostic work-up may include an ECG and ambulatory ECG to characterize the electrical subtype, and CMR imaging to characterize the morphological/functional subtype. Arrhythmias may be the sole cause of HFrEF or merely a bystander in the context of other causes of HF. Heart failure associated with abnormal cardiac conduction is defined as LV dysfunction due to abnormal electrical conduction and should be suspected in patients with LV dysfunction and a QRS duration ≥130 ms, without evidence of other causes for HF.199 It should also be considered in patients with implanted pacemakers or implantable cardioverter-defibrillators (ICDs) delivering RV pacing (see Section 6.2.2.2).200–203
Page 31 · PDF
cardiac implantable electronic device; CMR, cardiac magnetic resonance; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle branch block; PET, positron emission tomography; PMT, pacemaker tachycardia; PVC, premature ventricular contraction; RBBB, right bundle branch block; RV, right ventricular; SVT, supraventricular tachycardia; VT, ventricular tachycardia; WHF, worsening heart failure.
6. Management of chronic heart failure
Importantly, AMT and GDIT based on the underlying cause of HF, phenotypical characteristics, and comorbidities are discussed in other sections.
6.1. Guideline-directed medical therapy for heart failure
6.1.1. Goals of pharmacotherapy for patients with heart failure
The Task Force have decided to introduce the terms FMT and AMT, as described in Section 3 (Figure 3). Together FMT and AMT cover GDMT. For HFrEF, FMT currently includes beta-blockers, ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is, whereas for HFpEF it includes SGLT2-Is and MRAs.
Pharmacotherapy remains the cornerstone of treatment for stage C HF and should be implemented at doses used in RCTs in patients with HF before considering device therapy, and alongside non-pharmacological interventions (Figure 1 and Table 11). There are three major goals of treatment for patients with HF: (i) reduction in mortality; (ii) prevention of recurrent
Figure 9 Diagnosing arrhythmia-associated heart failure and heart failure with abnormal cardiac conduction. AF, atrial fibrillation; CIED,